Literature DB >> 19808345

Prevention of myofilament dysfunction by beta-blocker therapy in postinfarct remodeling.

Dirk J Duncker1, Nicky M Boontje, Daphne Merkus, Amanda Versteilen, Judith Krysiak, Giulia Mearini, Ali El-Armouche, Vincent J de Beer, Jos M J Lamers, Lucie Carrier, Lori A Walker, Wolfgang A Linke, Ger J M Stienen, Jolanda van der Velden.   

Abstract

BACKGROUND: Myofilament contractility of individual cardiomyocytes is depressed in remote noninfarcted myocardium and contributes to global left ventricular pump dysfunction after myocardial infarction (MI). Here, we investigated whether beta-blocker therapy could restore myofilament contractility. METHODS AND
RESULTS: In pigs with a MI induced by ligation of the left circumflex coronary artery, beta-blocker therapy (bisoprolol, MI+beta) was initiated on the first day after MI. Remote left ventricular subendocardial biopsies were taken 3 weeks after sham or MI surgery. Isometric force was measured in single permeabilized cardiomyocytes. Maximal force (F(max)) was lower, whereas Ca(2+) sensitivity was higher in untreated MI compared with sham (both P<0.05). The difference in Ca(2+) sensitivity was abolished by treatment of cells with the beta-adrenergic kinase, protein kinase A. beta-blocker therapy partially reversed F(max) and Ca(2+) sensitivity to sham values and significantly reduced passive force. Despite the lower myofilament Ca(2+) sensitivity in MI+beta compared with untreated myocardium, the protein kinase A induced reduction in Ca(2+) sensitivity was largest in cardiomyocytes from myocardium treated with beta-blockers. Phosphorylation of beta-adrenergic target proteins (myosin binding protein C and troponin I) did not differ among groups, whereas myosin light chain 2 phosphorylation was reduced in MI, which coincided with increased expression of protein phosphatase 1. beta-blockade fully restored the latter alterations and significantly reduced expression of protein phosphatase 2a.
CONCLUSIONS: beta-blockade reversed myofilament dysfunction and enhanced myofilament responsiveness to protein kinase A in remote myocardium after MI. These effects likely contribute to the beneficial effects of beta-blockade on global left ventricular function after MI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808345     DOI: 10.1161/CIRCHEARTFAILURE.108.806125

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  16 in total

1.  Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure.

Authors:  Jiang Zhang; Moltu J Guy; Holly S Norman; Yi-Chen Chen; Qingge Xu; Xintong Dong; Huseyin Guner; Sijian Wang; Takushi Kohmoto; Ken H Young; Richard L Moss; Ying Ge
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

2.  Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol.

Authors:  Y Li; J Shi; B F Yang; L Liu; C L Han; W M Li; D L Dong; Z W Pan; G Z Liu; J Q Geng; L Sheng; X Y Tan; D H Sun; Z H Gong; Y T Gong
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  'Integrative Physiology 2.0': integration of systems biology into physiology and its application to cardiovascular homeostasis.

Authors:  Diederik W D Kuster; Daphne Merkus; Jolanda van der Velden; Adrie J M Verhoeven; Dirk J Duncker
Journal:  J Physiol       Date:  2011-01-04       Impact factor: 5.182

4.  AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model.

Authors:  Philip W J Raake; Philipp Schlegel; Jan Ksienzyk; Julia Reinkober; Jens Barthelmes; Stefanie Schinkel; Sven Pleger; Walter Mier; Uwe Haberkorn; Walter J Koch; Hugo A Katus; Patrick Most; Oliver J Müller
Journal:  Eur Heart J       Date:  2012-01-19       Impact factor: 29.983

5.  Why does troponin I have so many phosphorylation sites? Fact and fancy.

Authors:  R John Solaro; Jolanda van der Velden
Journal:  J Mol Cell Cardiol       Date:  2010-02-25       Impact factor: 5.000

6.  β-Blockers in coronary artery disease management.

Authors:  G E Boudonas
Journal:  Hippokratia       Date:  2010-10       Impact factor: 0.471

Review 7.  Animal and in silico models for the study of sarcomeric cardiomyopathies.

Authors:  Dirk J Duncker; Jeroen Bakkers; Bianca J Brundel; Jeff Robbins; Jil C Tardiff; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-18       Impact factor: 10.787

8.  Myofilament calcium de-sensitization and contractile uncoupling prevent pause-triggered ventricular tachycardia in mouse hearts with chronic myocardial infarction.

Authors:  Raghav Venkataraman; Marcelo Perim Baldo; Hyun Seok Hwang; Tiago Veltri; Jose Renato Pinto; Franz J Baudenbacher; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2013-04-06       Impact factor: 5.000

Review 9.  Cardiac myosin binding protein C phosphorylation in cardiac disease.

Authors:  Diederik W D Kuster; Amira Cholid Bawazeer; Ruud Zaremba; Max Goebel; Nicky M Boontje; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2011-11-30       Impact factor: 2.698

10.  Back to the future: new techniques show that forgotten phosphorylation sites are present in contractile proteins of the heart whilst intensively studied sites appear to be absent.

Authors:  Steven B Marston; Jeffrey W Walker
Journal:  J Muscle Res Cell Motil       Date:  2009-07-25       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.